FDA and CMS Race to Prevent Federal-State AI Regulation Clash in Healthcare

Federal health regulators are quietly working to defuse a looming conflict with states over oversight of artificial intelligence in clinical care. The Food and Drug Administration and the Centers for Medicare and Medicaid Services are engaging state officials and industry stakeholders to avoid a patchwork of rules that could stifle innovation, according to people familiar with the discussions. States are increasingly exploring their own AI guardrails for medical devices and decision-support tools, raising concerns about overlapping and contradictory requirements. The FDA has long claimed primary authority over software as a medical device, while CMS oversees reimbursement and quality standards. With AI adoption accelerating in hospitals and clinics, the agencies face pressure to clarify jurisdictional boundaries before state bills gain momentum. Industry groups warn that divergent state laws could fragment the market and delay patient access to beneficial technologies. The behind-the-scenes coordination signals recognition that a unified federal framework is essential to maintain safety and promote innovation. The outcome may shape how quickly AI tools reach bedside care nationwide.